Home » EMA Grants Orphan Drug Designation to Advaxis Osteosarcoma Candidate
EMA Grants Orphan Drug Designation to Advaxis Osteosarcoma Candidate
The European Medicines Agency has awarded Advaxis orphan drug designation for its ADXS-HER2 for the treatment of osteosarcoma.
The immunotherapy targets cancers expressing human epidermal growth factor receptor 2, which is overexpressed in a percentage of solid tumors, including breast, gastric, bladder, brain, pancreatic, ovarian and pediatric bone cancer.
The candidate previously received orphan drug designation from the FDA for osteosarcoma.
Upcoming Events
-
21Oct